Boston Scientific reports strong growth in first quarter of 2017

Boston Scientific has announced its financial results for the first quarter of 2017, during which it reported a sales total of $2.16 billion (1.68 billion pounds).

This represents a year-on-year increase of ten percent on both a reported and operational basis, with GAAP earnings of $290 million recorded for the period, compared to $202 million during the same period a year ago.

The acquisition of EndoChoice Holdings contributed to this growth, with the firm's MedSurg, cardiovascular and rhythm management businesses all experiencing year-on-year growth.

Key highlights of the quarter include the acquisition of Symetis, the European approval of the Resonate family of cardiac resynchronisation therapy defibrillators (CRT-Ds) and a National Institute for Health and Care Excellence recommendation for the use of Boston Scientific CRT-Ds for treating patients with heart failure.

For the full year, a revenue growth range of approximately five to six percent is anticipated.

Mike Mahoney, chairman and chief executive officer at Boston Scientific, said: "We are pleased with our performance in the first quarter as we delivered excellent growth across our various businesses and geographies."

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.